Previous 10 | Next 10 |
Penumbra, Inc. to Present at Upcoming Investor Conferences PR Newswire ALAMEDA, Calif. , Aug. 24, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the...
Penumbra's operating performance has been up to par lately, including better-than-expected gross margins, but a rerating of growth med-tech has hit the shares harder than most. Management is trying to achieve a delicate balancing act between investing in REAL VR (a high-potential imme...
Penumbra, Inc. (PEN) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Jee Hamlyn-Harris - Head of Investor Relations Adam Elsesser - President and Chief Executive Officer Sandra Lesenfants - President, Interventional Maggie Yuen...
Penumbra press release ( NYSE: PEN ): Q2 GAAP EPS of -$0.10 misses by $0.11 . Revenue of $208.34M (+13.0% Y/Y) beats by $2.1M . Gross profit was $134.0 million, or 64.3% of total revenue for the second quarter of 2022, compared to $118.7 million, or 6...
Penumbra, Inc. Reports Second Quarter 2022 Financial Results PR Newswire ALAMEDA, Calif. , Aug. 4, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the secon...
SMID cap growth stocks have entered bear market territory, pressured by significant multiple compression from higher interest rates and unfolding economic deceleration. The Strategy underperformed in a difficult market, with declines most pronounced among several long-term holdings in...
Penumbra, Inc. to Present at the Canaccord Genuity 42nd Annual Growth Conference PR Newswire ALAMEDA, Calif. , July 27, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genui...
ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model looks to “Grow Markets and Take Market Share” targeting an ...
California-based medical device maker Penumbra, Inc. ( NYSE: PEN ) rose on Monday after RBC Capital Markets initiated its coverage with an Outperform rating and a price target of $195 per share to reflect a ~59% premium to the last close. The analysts led by Shagun Singh a...
Small cap growth stocks have entered bear market territory, pressured by significant multiple compression from higher interest rates and unfolding economic deceleration. The Strategy underperformed in a difficult market, with declines most pronounced among several long-term holdings i...
News, Short Squeeze, Breakout and More Instantly...
2024-07-13 17:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-03 18:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Penumbra, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024 PR Newswire ALAMEDA, Calif. , July 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial resu...